Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $465 | 7-10 days | |
500 μg | $1,850 | 7-10 days | |
1 mg | $3,100 | 7-10 days |
Biological Information | Immobilized Human CD20, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.33μg/ml determined by ELISA. |
Description | B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi) is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1. |
Species | Human |
Expression System | E. coli |
Tag | C-His-Avi |
Accession Number | P11836-1 |
Synonyms | MS4A2,Ly-44,LEU-16,MS4A1,Bp35,CD20 receptor,CVID5,MS4A-1,B1,S7,CD20S7,CD20 |
Construction | Ile141-Ser188 |
Protein Purity | > 95% as determined by Tris-Bis PAGE |
Molecular Weight | 16.8 kDa (predicted) same as Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Supplied as 0.22 μm filtered solution in 20 mM PB, 10% Glycerol, 0.4M Urea, 1 mM GSH, 0.1 mM GSSG (pH 7.0). |
Stability & Storage | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.